Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc. (CYCN): 4 pipeline candidates · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.4 months
0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for Cyclerion Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$14.1M
Cash
$2.8M
Quarterly Burn
$1.2M
Runway
7.4 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| cyc-126 | Preclinical |
| individualized therapy for trd | Preclinical |
| olinciguat | Phase 2 |
| praliciguat | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$253K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 84,550 | $130K |
| vanguard capital management llc | 32,274 | $50K |
| citadel advisors llc | 18,261 | $28K |
| blackrock, inc. | 16,797 | $26K |
| vanguard fiduciary trust co | 7,353 | $11K |
| fmr llc | 4,740 | $7K |
| group one trading llc | 192 | $295 |
| osaic holdings, inc. | 130 | $201 |
| activest wealth management | 100 | $155 |
| mai capital management | 100 | $155 |
Showing top 10 of 15 institutional holders of Cyclerion Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cyclerion Therapeutics, Inc.'s pipeline?
Cyclerion Therapeutics, Inc. (CYCN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cyclerion Therapeutics, Inc.'s lead drug candidate?
Cyclerion Therapeutics, Inc.'s most advanced tracked candidate is cyc-126 (Preclinical) for Treatment-resistant depression (TRD).
What is Cyclerion Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cyclerion Therapeutics, Inc. has approximately 7.4 months of cash runway.
What is Cyclerion Therapeutics, Inc.'s market capitalization?
Cyclerion Therapeutics, Inc.'s market capitalization is approximately $14.1M.
Who is the CEO of Cyclerion Therapeutics, Inc.?
Dr. Regina M. Graul Ph.D. is the chief executive officer of Cyclerion Therapeutics, Inc. (CYCN).
Get the full picture on Cyclerion Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.